Literature DB >> 18097279

A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.

Martin A Sieber1, Hubertus Pietsch, Jakob Walter, Wolfram Haider, Thomas Frenzel, Hanns-Joachim Weinmann.   

Abstract

OBJECTIVES: Several recent publications have suggested an association between the administration of gadolinium (Gd)-based contrast agents and the occurrence of Nephrogenic Systemic Fibrosis (NSF), an acquired disorder marked by skin thickening and fibrosis occurring in patients with severe renal dysfunction. The aim of this study was to establish a preclinical experimental setting to investigate the possible link between NSF and Gd-based contrast agents, and specifically the role of Gd and/or depletion of endogenous metal ions as possible triggers for NSF.
MATERIALS AND METHODS: Thirty-five healthy male rats received repeated intravenous injections of Magnevist (gadopentetate dimeglumine; Gd-DTPA), Omniscan (gadodiamide; Gd-DTPA-BMA), or gadodiamide without caldiamide at a dose of 2.5 mmol Gd/kg body weight over at least 20 days to simulate the exposure to Gd-containing contrast agents in patients with severe renal dysfunction. In addition, caldiamide (the excess ligand in Omniscan) and Gd-ethylenediamine tetraacetic acid (Gd-EDTA) as a positive control, and saline as a negative control were studied. Histopathologic and immunohistochemical analysis of the skin was performed. Gd and zinc concentrations were measured in skin, femur, and liver tissue by atomic emission spectrometry.
RESULTS: Rats receiving Gd-EDTA, gadodiamide without caldiamide, and Omniscan developed epidermal ulceration and acanthosis, dermo-epidermal clefts, minimal-to-slight dermal fibrosis, and increased dermal infiltration of different cells, partly positive for CD34 fibrocytes. No such NSF-like macroscopic lesions were observed in the saline, caldiamide, and Magnevist groups. High Gd concentrations in the skin were found in the Gd-EDTA, gadodiamide without caldiamide, and Omniscan groups. In the Magnevist group, Gd levels in the skin were 10-times lower than in the Omniscan-treated animals but elevated compared with saline.
CONCLUSIONS: A preclinical experimental setting has been established where NSF-like lesions could be observed. The link between the application of Gd-based contrast media and the induction of NSF-like lesions was established. The data indicate that the observed skin lesions are related to the release of Gd and not to the depletion of endogenous ions. The investigations further suggest potential importance of the stability of Gd-based contrast agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097279     DOI: 10.1097/RLI.0b013e31815e6277

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  51 in total

1.  Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?

Authors:  Sameh K Morcos
Journal:  Eur Radiol       Date:  2010-09-17       Impact factor: 5.315

2.  Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data.

Authors:  Sameh K Morcos; John Haylor
Journal:  World J Radiol       Date:  2010-11-28

3.  In vivo differentiation of complementary contrast media at dual-energy CT.

Authors:  John Mongan; Samira Rathnayake; Yanjun Fu; Runtang Wang; Ella F Jones; Dong-Wei Gao; Benjamin M Yeh
Journal:  Radiology       Date:  2012-07-09       Impact factor: 11.105

4.  The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.

Authors:  Thaddeus J Wadas; Christopher D Sherman; Jeffrey H Miner; James R Duncan; Carolyn J Anderson
Journal:  Magn Reson Med       Date:  2010-11       Impact factor: 4.668

5.  HDL as a contrast agent for medical imaging.

Authors:  David P Cormode; Juan C Frias; Yanqing Ma; Wei Chen; Torjus Skajaa; Karen Briley-Saebo; Alessandra Barazza; Kevin Jon Williams; Willem Jm Mulder; Zahi A Fayad; Edward A Fisher
Journal:  Clin Lipidol       Date:  2009-08

6.  Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent.

Authors:  Narasimharao Bhagavathula; Marissa DaSilva; Muhammad N Aslam; Michael K Dame; Roscoe L Warner; Yiru Xu; Gary J Fisher; Kent J Johnson; Richard Swartz; James Varani
Journal:  Invest Radiol       Date:  2009-08       Impact factor: 6.016

7.  Functional immunoassay technology (FIT), a new approach for measuring physiological functions: application of FIT to measure glomerular filtration rate (GFR).

Authors:  Christopher Peter Reinhardt; Michael J Germain; Ernest V Groman; Jeffrey G Mulhern; Rajesh Kumar; Dennis E Vaccaro
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-03

8.  Gadolinium-promoted cell cycle progression with enhanced S-phase entry via activation of both ERK and PI3K signaling pathways in NIH 3T3 cells.

Authors:  Li-Juan Fu; Jin-Xia Li; Xiao-Gai Yang; Kui Wang
Journal:  J Biol Inorg Chem       Date:  2008-10-25       Impact factor: 3.358

Review 9.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

10.  The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques.

Authors:  Alessandra Barazza; Courtney Blachford; Orli Even-Or; Victor A Joaquin; Karen C Briley-Saebo; Wei Chen; Xian-Cheng Jiang; Willem J M Mulder; David P Cormode; Zahi A Fayad; Edward A Fisher
Journal:  Bioconjug Chem       Date:  2013-05-10       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.